Advertisement
Grab your lab coat. Let's get started
Welcome!
Welcome!
Create an account below to get 6 C&EN articles per month, receive newsletters and more - all free.
It seems this is your first time logging in online. Please enter the following information to continue.
As an ACS member you automatically get access to this site. All we need is few more details to create your reading experience.
Not you? Sign in with a different account.
Not you? Sign in with a different account.
ERROR 1
ERROR 1
ERROR 2
ERROR 2
ERROR 2
ERROR 2
ERROR 2
Password and Confirm password must match.
If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)
ERROR 2
ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.
Outsourcing
Lonza adds fill and finish in a deal with Novartis
by Rick Mullin
July 4, 2019
| A version of this story appeared in
Volume 97, Issue 27
Lonza will enter the sterile drug fill-and-finish business by acquiring a Novartis facility in Stein, Switzerland. The facility includes liquid and lyophilized dosage-form capacity for clinical and commercial supply. Lonza will produce for Novartis and for third parties. The deal continues a trend among pharmaceutical services firms to build up finished-drug manufacturing capacity. Last month Catalent said it will acquire Bristol-Myers Squibb’s solid, biologics, and sterile product facility in Anagni, Italy.
Chemical & Engineering News
ISSN 0009-2347
Copyright © 2024 American Chemical Society
You might also like...
The power is now in your (nitrile gloved) hands
Sign up for a free account to get more articles. Or choose the ACS option that’s right for you.
Already have an ACS ID? Log in
Join the conversation
Contact the reporter
Submit a Letter to the Editor for publication
Engage with us on Twitter